Assertio Therapeutics, Inc. (ASRT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ASRT POWR Grades
- ASRT scores best on the Value dimension, with a Value rank ahead of 95.81% of US stocks.
- The strongest trend for ASRT is in Momentum, which has been heading down over the past 49 weeks.
- ASRT's current lowest rank is in the Growth metric (where it is better than 1.34% of US stocks).
ASRT Stock Summary
- With a price/sales ratio of 0.37, Assertio Holdings Inc has a higher such ratio than only 6.15% of stocks in our set.
- The volatility of Assertio Holdings Inc's share price is greater than that of 95.09% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ASRT comes in at -58.9% -- higher than that of just 4.87% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Assertio Holdings Inc, a group of peers worth examining would be CLNE, SHO, EOLS, RES, and EEX.
- ASRT's SEC filings can be seen here. And to visit Assertio Holdings Inc's official web site, go to www.assertiotx.com.
ASRT Valuation Summary
- In comparison to the median Healthcare stock, ASRT's EV/EBIT ratio is 105.8% lower, now standing at -1.7.
- Over the past 243 months, ASRT's price/earnings ratio has gone up 3.6.
- Over the past 243 months, ASRT's EV/EBIT ratio has gone up 3.
Below are key valuation metrics over time for ASRT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ASRT | 2021-08-31 | 0.4 | 0.5 | -1.1 | -1.7 |
| ASRT | 2021-08-30 | 0.4 | 0.5 | -1.1 | -1.7 |
| ASRT | 2021-08-27 | 0.4 | 0.5 | -1.1 | -1.7 |
| ASRT | 2021-08-26 | 0.4 | 0.5 | -1.0 | -1.6 |
| ASRT | 2021-08-25 | 0.4 | 0.5 | -1.0 | -1.6 |
| ASRT | 2021-08-24 | 0.4 | 0.5 | -1.0 | -1.6 |
ASRT Growth Metrics
- Its 4 year revenue growth rate is now at -53.65%.
- Its 3 year cash and equivalents growth rate is now at -39.72%.
- Its 3 year revenue growth rate is now at -41.9%.
The table below shows ASRT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 116.953 | -23.675 | -44.5 |
| 2021-03-31 | 112.197 | -44.735 | -64.83 |
| 2020-12-31 | 106.275 | -65.572 | -28.144 |
| 2020-09-30 | 135.325 | -51.735 | -196.417 |
| 2020-06-30 | 155.907 | -3.393 | -182.564 |
| 2020-03-31 | 192.493 | 38.217 | -161.67 |
ASRT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ASRT has a Quality Grade of C, ranking ahead of 35.61% of graded US stocks.
- ASRT's asset turnover comes in at 0.367 -- ranking 129th of 680 Pharmaceutical Products stocks.
- NOVN, ARWR, and RIOT are the stocks whose asset turnover ratios are most correlated with ASRT.
The table below shows ASRT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.367 | 0.819 | -1.136 |
| 2021-03-31 | 0.343 | 0.800 | -1.673 |
| 2020-12-31 | 0.354 | 0.813 | -0.761 |
| 2020-09-30 | 0.380 | 0.884 | -1.944 |
| 2020-06-30 | 0.337 | 0.927 | -1.098 |
| 2020-03-31 | 0.332 | 0.957 | -0.485 |
ASRT Price Target
For more insight on analysts targets of ASRT, see our ASRT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.20 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ASRT Stock Price Chart Interactive Chart >
ASRT Price/Volume Stats
| Current price | $1.02 | 52-week high | $5.80 |
| Prev. close | $0.98 | 52-week low | $0.85 |
| Day low | $0.97 | Volume | 959,100 |
| Day high | $1.03 | Avg. volume | 2,046,910 |
| 50-day MA | $0.99 | Dividend yield | N/A |
| 200-day MA | $2.04 | Market Cap | 45.38M |
Assertio Therapeutics, Inc. (ASRT) Company Bio
Assertio Therapeutics, Inc. (formerly DepoMed) develops products for pain and other central nervous system conditions in the United States. The company was founded in 1995 and is focused in Newark, California.
Latest ASRT News From Around the Web
Below are the latest news stories about Assertio Holdings Inc that investors may wish to consider to help them evaluate ASRT as an investment opportunity.
Assertio Holdings, Inc. to Participate in Upcoming Investor EventsLAKE FOREST, Ill., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT) today announced that the Company’s Chief Executive Officer, Dan Peisert, and Chief Financial Officer, Paul Schwichtenberg, will present and host individual meetings with investors at the following events: LD Micro Main EventPresentingOctober 12 – 14, 2021 (date and time to be announced) Stifel 2021 Virtual Healthcare Conference PresentingNovember 15 – 17, 2021 (date and time |
Bausch Pays $300M For Diabetes Drug Lawsuit: ReutersReuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on diabetes drug Glumetza. The FDA first approved Glumetza, a once-daily extended-release version of metformin, owned by Depomed, now known as Assertio Holdings Inc (NASDAQ: ASRT), and Santarus, which Bausch later acquired. Lupin Pharmaceuticals created its generic version of Glumetza, set to launch in late 2012. The lawsuit alleged that As |
Bausch to pay $300 million in antitrust suit over diabetes drugBausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800% price hike in 2015. Lawyers for companies that bought Glumetza and filed the class action against Bausch disclosed the deal in a court filing Wednesday, asking U.S. District Judge William Alsup in San Francisco to approve it. "Plaintiffs are pleased with the settlement, which recovers for the class a very substantial portion of the overcharges that they suffered," Steve Shadowen, a lawyer for the purchasers, said in an email. |
Bausch to pay $300 mln in antitrust suit over diabetes drugBausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800% price hike in 2015. Lawyers for companies that bought Glumetza and filed the class action against Bausch disclosed the deal in a court filing Wednesday, asking U.S. District Judge William Alsup in San Francisco to approve it. "Plaintiffs are pleased with the settlement, which recovers for the class a very substantial portion of the overcharges that they suffered," Steve Shadowen, a lawyer for the purchasers, said in an email. |
New Strong Sell Stocks for September 9thASRT, CVGW, NTRB, ITRG, and KNBWY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2021 |
ASRT Price Returns
| 1-mo | 9.68% |
| 3-mo | -17.74% |
| 6-mo | -45.92% |
| 1-year | -64.81% |
| 3-year | -95.69% |
| 5-year | -98.94% |
| YTD | -28.69% |
| 2020 | -71.39% |
| 2019 | -65.37% |
| 2018 | -55.16% |
| 2017 | -55.33% |
| 2016 | -0.61% |
Continue Researching ASRT
Here are a few links from around the web to help you further your research on Assertio Therapeutics Inc's stock as an investment opportunity:Assertio Therapeutics Inc (ASRT) Stock Price | Nasdaq
Assertio Therapeutics Inc (ASRT) Stock Quote, History and News - Yahoo Finance
Assertio Therapeutics Inc (ASRT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...